NO924820L - Anvendelse av 5,10,15,20 tetrakis(r-karboksyfenyl)porfin for aa paavise og behandle lungekreft - Google Patents

Anvendelse av 5,10,15,20 tetrakis(r-karboksyfenyl)porfin for aa paavise og behandle lungekreft

Info

Publication number
NO924820L
NO924820L NO92924820A NO924820A NO924820L NO 924820 L NO924820 L NO 924820L NO 92924820 A NO92924820 A NO 92924820A NO 924820 A NO924820 A NO 924820A NO 924820 L NO924820 L NO 924820L
Authority
NO
Norway
Prior art keywords
carboxyphenyl
tetrakis
porphin
pause
treatment
Prior art date
Application number
NO92924820A
Other languages
English (en)
Other versions
NO924820D0 (no
Inventor
Dean A Cole
David C Moody
L Edward Ellinwood
M Gerard Klein
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO924820D0 publication Critical patent/NO924820D0/no
Publication of NO924820L publication Critical patent/NO924820L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1206—Administration of radioactive gases, aerosols or breath tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/80—Fluorescent dyes, e.g. rhodamine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/805—Optical property

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Atmospheric Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Fremgangsmåte som anvender tetraarylporfyriner og spesielt 5,10,15,20-tetrakis(4-karboksyfenyl)porfin som et fluorescent påvisningsmiddel for lungekreft og som et radiopåvisningsmiddel for lungekreft som kompleks med 67Cu. Sistnevnte kompleks utgjør også en kilde for beta- stråling for selektiv ødeleggelse av ondartede lunge- svulster, såvel som for gammastråling som er anvendelig for bildeanalyse av stedene ned kreft ved for eksempel enkeltfotonemisjons databehandlet tomografi, begge in vivo. Kobber-64 kan erstatte 67Cu hvis kun de radio- påvisende særtrekk er av interesse. Det lettere kobber- isotop sender ut positroner, og positronemisjons- tomografiteknikker kan brukes for å lokalisere det ondartede vevsmateriale.
NO92924820A 1990-06-15 1992-12-14 Anvendelse av 5,10,15,20 tetrakis(r-karboksyfenyl)porfin for aa paavise og behandle lungekreft NO924820L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/539,999 US5162231A (en) 1989-10-25 1990-06-15 Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung
PCT/US1991/004132 WO1991019977A1 (en) 1990-06-15 1991-06-17 USING 5,10,15,20-TETRAKIS(r-CARBOXYPHENYL)PORPHINE FOR DETECTING AND TREATING LUNG CANCER

Publications (2)

Publication Number Publication Date
NO924820D0 NO924820D0 (no) 1992-12-14
NO924820L true NO924820L (no) 1993-02-12

Family

ID=24153544

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92924820A NO924820L (no) 1990-06-15 1992-12-14 Anvendelse av 5,10,15,20 tetrakis(r-karboksyfenyl)porfin for aa paavise og behandle lungekreft

Country Status (15)

Country Link
US (2) US5162231A (no)
EP (1) EP0533845B1 (no)
JP (1) JP3047468B2 (no)
KR (1) KR0171393B1 (no)
AT (1) ATE251750T1 (no)
AU (2) AU8061491A (no)
BR (1) BR9106563A (no)
CA (1) CA2085464C (no)
DE (1) DE69133325T2 (no)
DK (1) DK0533845T3 (no)
FI (1) FI925673A (no)
HU (1) HUT63499A (no)
NO (1) NO924820L (no)
RU (1) RU2114430C1 (no)
WO (2) WO1991019978A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622685A (en) * 1990-05-30 1997-04-22 Deutches Krebsforchunszentrum Stiftung Des Offentlichen Rechts Polyether-substituted porphyrin anti-tumor agents
US5252698A (en) * 1992-10-09 1993-10-12 Sri International Metal ion porphyrin-containing poly(azine)
US5464741A (en) * 1993-10-08 1995-11-07 Henwell, Inc. Palladium (II) octaethylporphine alpha-isothiocyanate as a phosphorescent label for immunoassays
US6490330B1 (en) * 1994-04-12 2002-12-03 The Regents Of The University Of California Production of high specific activity copper -67
US5716958A (en) * 1994-10-27 1998-02-10 Tobishi Pharmaceutical Co., Ltd. Amino acid derivative having anti-CCK activity
US5756726A (en) * 1995-06-02 1998-05-26 Pharmacyclics, Inc. Methods of producing singlet oxygen using compounds having improved functionalization
ES2198767T3 (es) 1997-11-03 2004-02-01 Duke University Porfirinas sustituidas.
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
JP4501128B2 (ja) 1999-01-25 2010-07-14 ナショナル ジュウィッシュ ヘルス 置換ポルフィリン
US6984498B2 (en) * 1999-12-27 2006-01-10 Adair Edwin L Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6750037B2 (en) * 1999-12-27 2004-06-15 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6190877B1 (en) * 1999-12-27 2001-02-20 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques
US6575888B2 (en) * 2000-01-25 2003-06-10 Biosurface Engineering Technologies, Inc. Bioabsorbable brachytherapy device
KR100390771B1 (ko) * 2000-08-31 2003-07-10 한국화학연구원 광역학 치료(ｐｄｔ)용 광민감성 물질로 유용한 포르피린유도체
US6838248B2 (en) 2000-11-17 2005-01-04 Biomoda, Inc. Compositions and methods for detecting pre-cancerous conditions in cell and tissue samples using 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine
CA2436245C (en) * 2001-01-19 2013-04-23 National Jewish Medical And Research Center Medicament for protection in radiotherapy
AU2002312194B8 (en) 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
US6566517B2 (en) 2001-06-06 2003-05-20 Brookhaven Science Associates, Llc Metalloporphyrins and their uses as imageable tumor-targeting agents for radiation therapy
AU2003216502B2 (en) * 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
AU2003237500A1 (en) 2002-06-07 2003-12-22 Duke University Substituted porphyrins
EP1374912B1 (en) * 2002-06-21 2006-08-16 Edwin L. Adair Use of metaloporphyrins for treatment of arteriosclerotic lesions
CN1688303A (zh) 2002-07-23 2005-10-26 密歇根大学董事会 用于抗血管发生疗法的四硫代钼酸四丙铵及相关化合物
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
US6989443B2 (en) * 2004-06-28 2006-01-24 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US6995260B2 (en) * 2004-05-20 2006-02-07 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
WO2007136967A2 (en) * 2006-05-17 2007-11-29 Koninklijke Philips Electronics, N.V. Retrospective sorting of 4d ct into breathing phases based on geometric analysis of imaging fiducials
US9957293B2 (en) * 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
US8287839B2 (en) * 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8444953B2 (en) * 2007-03-22 2013-05-21 Brookhaven Science Associates, Llc Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof
US20080279781A1 (en) * 2007-05-10 2008-11-13 Brookhaven Science Associates, Llc Glycosylated Carboranylporphyrins and Uses Thereof
EP2300003B1 (en) 2008-05-23 2014-03-05 National Jewish Health Compounds for use in treating injury associated with exposure to an alkylating species
ES2651068T3 (es) * 2009-07-17 2018-01-24 Bioaffinity Technologies, Inc. Sistema y procedimiento de análisis de muestras marcadas con 5,10,15,20 tetraquis(4 carboxifenil)porfirina (TCPP)
JP2019523783A (ja) 2016-06-16 2019-08-29 オンコセレクト セラピューティクス，エルエルシー がんの治療に有用なポルフィリン化合物及び組成物
CN107589189B (zh) * 2017-09-06 2018-07-10 中国农业科学院饲料研究所 一种氟甲喹的手性对映体的检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4930516B1 (en) * 1985-11-13 1998-08-04 Laser Diagnostic Instr Inc Method for detecting cancerous tissue using visible native luminescence
US4783529A (en) * 1985-12-03 1988-11-08 Research Corporation Technologies Rapid synthesis of radiolabeled porphyrin complexes for medical application
US4857300A (en) * 1987-07-27 1989-08-15 Cytocorp, Inc. Cytological and histological fixative formulation and methods for using same

Also Published As

Publication number Publication date
HU9203923D0 (en) 1993-03-29
KR0171393B1 (ko) 1999-05-15
BR9106563A (pt) 1993-06-22
FI925673A0 (fi) 1992-12-14
RU2114430C1 (ru) 1998-06-27
ATE251750T1 (de) 2003-10-15
WO1991019978A1 (en) 1991-12-26
EP0533845A4 (en) 1993-11-18
DE69133325D1 (de) 2003-11-13
CA2085464A1 (en) 1991-12-16
WO1991019977A1 (en) 1991-12-26
FI925673A (fi) 1992-12-14
AU8061491A (en) 1992-01-07
EP0533845B1 (en) 2003-10-08
EP0533845A1 (en) 1993-03-31
DE69133325T2 (de) 2004-07-29
US5391547A (en) 1995-02-21
JP3047468B2 (ja) 2000-05-29
AU8190691A (en) 1992-01-07
AU670743B2 (en) 1996-08-01
US5162231A (en) 1992-11-10
CA2085464C (en) 2002-12-17
NO924820D0 (no) 1992-12-14
JPH06500164A (ja) 1994-01-06
DK0533845T3 (da) 2004-02-16
HUT63499A (en) 1993-08-30

Similar Documents

Publication Publication Date Title
NO924820D0 (no) Anvendelse av 5,10,15,20 tetrakis(r-karboksyfenyl)porfin for aa paavise og behandle lungekreft
RU92016479A (ru) Применение 5,10,15,20-тетракис (4-карбоксифенил) порфина для обнаружения и лечения рака легких
Spiess et al. Bone cancers induced by 224Ra (Th X) in children and adults
DeRiemer et al. BLEDTA: tumor localization by a bleomycin analog containing a metal-chelating group
Hambright et al. The distribution of various water soluble radioactive metalloporphyrins in tumor bearing mice
EP0643583A4 (en) DETECTION AND THERAPY OF TUMORS AND LESIONS DURING PEROPERATORY, INTRAVASCULAR AND ENDOSCOPIC EXAMINATION.
FR2297034B1 (no)
Mäntylä et al. Regional blood flow in human tumours with special reference to the effect of radiotherapy
WO1990014106A3 (en) 99mtc(iii) myocardial imaging agents that are effective in humans
Nakajima et al. TUMOR IMAGING WITH [111niIn] MONO‐DTPA‐ETHYLENEGLYCOL‐Ga‐DEUTEROPORPHYRIN
Murugesan et al. Preparation and biological evaluation of the new chlorin photosensitizer T3, 4BCPC for detection and treatment of tumors
Lawrence Artificial radio-activity and neutron rays in biology and medicine
Doi et al. Preparation of 109Pd-hematoporphyrin for selective lymphatic ablation using N-methylhematoporphyrin
KR890701134A (ko) 중성자 포착 종양요법을 위한 리포조옴으로 캡슐화된 화합물의 조성물 및 사용방법
de Lima Radioisotopes in medicine
Liukkonen et al. Levels of 82Kr from the decay of 35 h 82Br
Van Der Werff Clinical investigations on the use of radioactive gallium (Ga66 and Ga67) in bone diseases
Magerstadt et al. Preparation, 252Cf-plasma-desorption mass spectrometry and radiometal exchange of the Pb2+ and Bi3+ complexes of a hexalactam macrocycle
Coursey Needs for radioactivity standards and measurements in the life sciences
Sklaroff Treatment of hemangiomas with the strontium-90 beta-ray applicator
Ortalli et al. Gamma-rays from Mössbauer sources: a low-dose approach to cancer therapy
DE3875290D1 (de) Verwendung eines vehikels mit hoher affinitaet zu tumoren.
Laster et al. In vivo studies in NCT with a boronated porphyrin and tumor growth delay as an end point
Myers Neutron-Radioactivated Pure Chromium Crystals as Sources of Gamma Rays for Radiation Chemotherapy
Heikkonen et al. Partition coefficient ratios and tumour perfusion studied with 85mKr and 133Xe